Evidence map›Paper›PMID 32236577›Full record

ArticleInternational journal of molecular medicine2020

Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non‑small‑cell lung carcinoma via miR‑1183 and PI3K/PKB pathway.

Wenwen Wu, Wei Xi, Huimin Li, Mengxiang Yang, Xialei Yao

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. CircACC1 Promotes NSCLC ProliferationFrontiers in genetics · 2021
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wenwen WuDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
Wei XiDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
Huimin LiDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
Mengxiang YangDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
Xialei YaoDepartment of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China.
Liaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑small cell lung carcinoma (NSCLC) accounts for 85% of all lung cancers and the five‑year survival rate is ~1% in the late stage. Circular RNAs (circRNAs) were reported to be involved in the progression of diverse human cancers. However, the role of circ‑ACACA in NSCLC progression remains elusive. Quantitative polymerase chain reaction was conducted to detect the expression levels of circ‑ACACA and microRNA (miR)‑1183 in NSCLC tissues and cells. A Cell Counting Kit‑8 assay and transwell assay were employed to check proliferation and migration, respectively. Metabolic alternations in NSCLC cells were monitored by the Seahorse XFe96 analyzer. The protein levels of cellular myelocytomatosis, matrix metallopeptidase 9, glucose transporter 1, phosphatase and tensin homolog, phosphoinositide 3‑kinases (PI3K), phosphorylated PI3K (p‑PI3K), protein kinase B (PKB) and p‑PKB in samples were measured by western blotting. The interaction between circ‑ACACA and miR‑1183 was predicted by circular RNA Interactome, which was verified by dual‑luciferase reporter assay, RNA immunoprecipitation assay and RNA pull‑down assay. Xenograft tumor model was established to investigate the biological roles of circ‑ACACA in vivo. The level of circ‑ACACA was markedly upregulated in NSCLC tissues and cells, which was contrary to the expression of miR‑1183. Knockdown of circ‑ACACA inhibited proliferation and migration of NSCLC cells and also reduced the glycolysis rate. In addition, miR‑1183 was a target of circ‑ACACA and its downregulation reversed circ‑ACACA silencing‑mediated inhibitory impact on NSCLC progression. Further studies indicated that circ‑ACACA regulated the PI3K/PKB pathway through interacting with miR‑1183 and downregulation of circ‑ACACA suppressed tumor growth. Knockdown of circ‑ACACA impeded NSCLC progression by sponging miR‑1183 and inactivating the PI3K/PKB signaling pathway.

Indexed as

A549 CellsAcetyl-CoA CarboxylaseAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationDisease ProgressionDown-RegulationGene Expression Regulation, NeoplasticGlycolysisHumansLung NeoplasmsMaleMiceMice, Inbred BALB CACACA protein, humanAcetyl-CoA CarboxylaseMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Circular

Identifiers

PMID32236577
PMCPMC7169939
OpenAlexW3013012472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.